News and Announcements
Amogen Pioneer Newly Onboard with Actinogen Medical
- Published November 16, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Dr George Morstyn is joining Actinogen Medical as a non-executive director as of December 1, 2017.
- He brings extensive drug development experience to the role, with many new products receiving marketing approval.
- Dr Morstyn will work with Actinogen’s high calibre team to guide and optimise the development of XanamemTM.
As announced November 2, 2017, Actinogen Medical (ASX: ACW) proudly welcomes Dr George Morstyn, as a non-executive director on the board, beginning December 1, 2017. Dr Morstyn, a pioneer drug developer and former Amgen Inc. Executive, usher extensive drug development studies to the role with massive new products receiving approval of the market and launching products during his tenureship at Amgen.
Having worked in the 1980’s with the legendary Professor Don Metcalf “Order of Australia and Companion of the Order, regarded as the father of modern haematology”, at the Walter and Eliza Hall Institute. Dr Morstyn actively assisted establishing and pioneering the clinical development of the haemopoietic colony stimulating factors, the present champion in the standard treatment of patients suffering from cancer after chemotherapy. He worked as esteemed Senior Vice-President of Development and Chief Medical Officer at US biotech tower, Amgen (NASDAQ: AMGM, market capitalisation: US$128 billion), upon joining Amgen in its early formative years in 1991, when the company was a blossoming biotech. At Amgen, he was the key person for the development of medications, treatments across all therapeutic areas, including neuroscience as well.
Dr Morstyn will join with Actinogen’s highly renowned team to lead and optimise the development of XanamemTM for Alzheimer’s disease and various neurodegenerative conditions. Under his strong leadership in the medical arena, he dominated the marketing approval of many new products and subsequent successful commercial launches.
About Actinogen Medical Ltd (ASX: ACW)
Actinogen Medical Limited (ASX:ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Company Updates
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
